What are the medication dosing guidelines for patients with Post-Traumatic Stress Disorder (PTSD)?

Medication Dosing Guidelines for Post-Traumatic Stress Disorder (PTSD)

Prazosin is the first-line pharmacological treatment for PTSD-associated nightmares, with sertraline and paroxetine recommended as first-line treatments for overall PTSD symptoms. 1

First-Line Pharmacological Treatments

SSRIs (First-line for overall PTSD symptoms)

• Sertraline (Zoloft)

  • Initial dose: 25 mg/day for first week
  • Therapeutic range: 50-200 mg/day
  • Mean effective dose in clinical trials: 146-151 mg/day
  • Administered as a single daily dose with or without food 2

• Paroxetine (Paxil)

  • Initial dose: 20 mg/day
  • Therapeutic range: 20-50 mg/day
  • Dose changes should occur in 10 mg/day increments at intervals of at least 1 week
  • Maximum dose: 50 mg/day
  • Administered as a single daily dose with or without food, usually in the morning 3

Alpha-1 Adrenergic Antagonist (First-line for PTSD-associated nightmares)

• Prazosin
  • Initial dose: 1 mg at bedtime
  • Increase by 1-2 mg every few days until effective dose is reached
  • Average effective dose: 3 mg (range 1-15 mg)
  • Higher doses (9.5-15.6 mg/day) may be needed for combat-related PTSD
  • Monitor for orthostatic hypotension 1
  • Note: Recent evidence has led to downgrading the recommendation strength, but prazosin remains the first choice for PTSD-related nightmares 1

Second-Line Pharmacological Treatments

For PTSD-Associated Nightmares

• Clonidine

  • Dose range: 0.2-0.6 mg in divided doses
  • Monitor for hypotension
  • Level C recommendation (lower evidence than prazosin) 1

• Trazodone

  • Dose range: 25-600 mg (mean effective dose: 212 mg)
  • Common side effects: daytime sedation, dizziness, headache, priapism, orthostatic hypotension
  • Level C recommendation 1

Other Second-Line Options for PTSD Symptoms

• Venlafaxine

  • Dose range: 32.5-300 mg/day
  • Note: Limited efficacy for nightmares specifically 1

• Fluoxetine

  • Dose range: 20-60 mg/day
  • Similar efficacy to other SSRIs 4

• Escitalopram

  • Initial dose: 10 mg daily for 4 weeks
  • May increase to 20 mg daily thereafter 5

Third-Line and Adjunctive Treatments

• Topiramate

  • Initial dose: 25 mg/day
  • Titrate up to effect or maximum 400 mg/day
  • Median effective dose: 150 mg/day 1

• Atypical Antipsychotics (as augmentation)

  • Consider for patients with partial response to SSRIs
  • Risperidone has the strongest evidence as an add-on therapy 6

• Low-dose Cortisol

  • Dose: 10 mg/day (either in morning or half at noon and half in evening)
  • Limited evidence but may reduce nightmare frequency 1

• Gabapentin

  • Dose range: 685-1344 mg/day
  • Higher doses (mean 1344 mg) associated with better response 1

• Fluvoxamine

  • Dose range: 50-300 mg/day
  • Limited evidence but may reduce combat-related nightmares 1

Medications to Avoid in PTSD

• Benzodiazepines

  • Not recommended for PTSD treatment
  • May worsen PTSD symptoms and have potential for dependence 1, 6

• Cannabis and cannabis-derived products

  • Not recommended due to insufficient evidence of efficacy and potential harms 1

Special Considerations

• Elderly or Debilitated Patients

  • Start with lower doses (e.g., paroxetine 10 mg/day)
  • Increase doses more gradually
  • Maximum dose should not exceed 40 mg/day 3

• Pregnancy (Third Trimester)

  • Consider tapering SSRIs during third trimester due to potential neonatal complications
  • Carefully weigh risks and benefits 3

• Combination Treatment

  • Consider combining psychotherapy (particularly trauma-focused CBT) with medication for optimal outcomes 1

Monitoring and Duration of Treatment

• Assess response using standardized symptom rating scales 1
• Continue effective treatment for at least 6-12 months to decrease relapse rates 4
• Periodically reassess to determine need for continued treatment 2, 3
• Monitor for side effects, particularly orthostatic hypotension with prazosin and clonidine 1

Common Pitfalls and Caveats

• Antidepressant efficacy may be reduced when combined with prazosin (particularly in combat veterans) 1
• SSRIs may initially worsen anxiety symptoms; consider starting with subtherapeutic "test" dose 1
• Discontinuation syndrome can occur with abrupt cessation of shorter-acting SSRIs (particularly paroxetine) 1
• Response rates to SSRIs rarely exceed 60%, with full remission in only 20-30% of patients 6
• Nefazodone is not recommended as first-line therapy due to increased risk of hepatotoxicity 1